KOL

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Retrieved on: 
Thursday, November 30, 2023
Urinary tract infection, University of California, Disease, Cystic fibrosis, Mortality, Pseudomonas aeruginosa, University, Phage therapy, Infection, Part, BOLT, Patient, NESS, KOL, Pharmaceutical industry

(University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.

Key Points: 
  • (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
  • Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
  • BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections.
  • P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Retrieved on: 
Thursday, November 30, 2023
Dermatology, Probability, FDA, Nevoid basal-cell carcinoma syndrome, Disease, Sol–gel process, Breakthrough, BCC, Patient, Carcinoma, Executive director, NESS, KOL, Pharmaceutical industry

Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.

Key Points: 
  • Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.
  • "We are pleased to initiate patient screening in this Phase 3 trial that has been long awaited by the Gorlin syndrome patient community,” said Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel.
  • Sol-Gel will conduct the Phase 3 study to investigate SGT-610 in approximately 140 subjects at approximately 40 experienced clinical centers in North America, United Kingdom and Europe.
  • The event will highlight the patient’s experience through the eyes of a Gorlin syndrome patient as well as discuss the therapeutic potential of SGT-610 to prevent new BCCs in Gorlin syndrome patients and Sol-Gel’s Phase 3 trial.

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Retrieved on: 
Wednesday, November 29, 2023
Patient, Colistin, Culture, Infection, Division, Șaeș, Tobramycin, Aztreonam, Lung, Cystic fibrosis, FEV1, Pediatrics, Therapy, Pseudomonas aeruginosa, University, Phage therapy, Part, Safety, NESS, KOL, Pharmaceutical industry

“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX.

Key Points: 
  • “These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Patients were on the same inhaled antibiotic (tobramycin, aztreonam, or colistin) from Day 1-10 (treatment period) and through Day 28 of the study.
  • BX004 vs. placebo showed a positive clinical effect in a predefined subgroup of patients with reduced baseline lung function (FEV1
  • BiomX management will host a conference call and webcast today at 9:00 am ET to review the results of Part 2 of the Phase 1b/2a trial results.

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

Retrieved on: 
Tuesday, November 28, 2023
RNA, RNA interference, Q&A, Former, Alnylam Pharmaceuticals, Therapy, ECO, Doctor of Philosophy, KOL

The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals, and David Butler, PhD, Chief Technology Officer at Hongene Biotech Corporation.

Key Points: 
  • The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals, and David Butler, PhD, Chief Technology Officer at Hongene Biotech Corporation.
  • These distinguished experts will discuss the RNAi therapeutics manufacturing landscape and share their perspectives on the potential role of an enzymatic route of synthesis in commercial-scale production.
  • During the event, Codexis management will also provide an overview of the ECO Synthesis™ platform and the associated commercial opportunity.
  • A replay of the presentation will be archived in the Investor Relations section of the Company’s website, https://ir.codexis.com , following the event.

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Retrieved on: 
Tuesday, November 28, 2023
Dermatology, FDA, Nevoid basal-cell carcinoma syndrome, Disease, Sol–gel process, Doctor of Philosophy, Therapy, Genetic disorder, HHI, Growth, BCC, Patient, Carcinoma, Executive director, NESS, KOL, Pharmaceutical industry

The event will feature Julie Breneiser (Executive Director, Gorlin Syndrome Alliance) and Ervin Epstein Jr., MD (Co-Founder of PellePharm Inc.), who will discuss the significant disease burden of Gorlin syndrome patients and lack of effective therapies.

Key Points: 
  • The event will feature Julie Breneiser (Executive Director, Gorlin Syndrome Alliance) and Ervin Epstein Jr., MD (Co-Founder of PellePharm Inc.), who will discuss the significant disease burden of Gorlin syndrome patients and lack of effective therapies.
  • Gorlin syndrome is a rare genetic disorder associated with growth of multiple basal cell carcinomas.
  • SGT-610 has been granted Orphan Drug Designation as well as Breakthrough Designation by the FDA.
  • Alon Seri-Levy, PhD (Co-Founder and Chief Executive Officer, Sol-Gel Therapeutics) will provide an overview of the upcoming SGT-610 Phase 3 study, including strategies intended to optimize success of the study, and insights on market potential.

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

Retrieved on: 
Tuesday, November 28, 2023
VISTA, Cancer, Associate, Professor, Oncology, Patient, Tumor microenvironment, TME, KOL, Pharmaceutical industry

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors.

Key Points: 
  • SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors.
  • Details are as follows:
    The event will feature presentations from two key opinion leaders in immuno-oncology:
    Michael A. Curran, Ph.D., Associate Professor at MD Anderson Cancer Center Department of Immunology, who will discuss key challenges with current cancer therapies and the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment (TME) and drive anti-tumor activity.
  • Evan Y. Yu, M.D., Professor and Medical Oncology Section Head at Fred Hutchinson Cancer Center, who will join Kineta leadership to discuss immuno-oncology clinical trials and review the new positive monotherapy data from the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors.
  • A live question and answer session will follow the formal presentations.

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Retrieved on: 
Tuesday, November 28, 2023
MD Anderson Cancer Center, Conference, Lung cancer, CAB, Nivolumab, MD, SAN, Doctor of Philosophy, AXL, Conditional, Therapy, KOL, Pharmaceutical industry

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET.

Key Points: 
  • SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET.
  • To register, click here .
  • The event will feature Carl M. Gay, MD, PhD (MD Anderson Cancer Center), who will review the Phase 2 clinical trial data of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in refractory non-small cell lung cancer (NSCLC) and include a discussion of AXL as a contributor of therapeutic resistance and a marker of poor prognosis in NSCLC.
  • A live question and answer session will follow the presentation.

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Retrieved on: 
Wednesday, November 22, 2023
University of Alabama, IND, FDA, Multiple myeloma, BCMA, ODD, Society, Amyloidosis, University, AL amyloidosis, Hematology, Poster, Patient, KOL, Assistant professor, Pharmaceutical industry

To register for the event, click here.

Key Points: 
  • To register for the event, click here.
  • NXC-201 is a BCMA-targeted investigational CAR-T cell therapy.
  • NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma.
  • A live question and answer session will follow the formal presentations.

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Retrieved on: 
Tuesday, November 21, 2023
Mother, Child, University of Chile, MD, Pediatric endocrinology, Research, University, LUMO, KOL, Pharmaceutical industry

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.

Key Points: 
  • AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.
  • Management will be joined by three esteemed thought leaders in the field of endocrinology:
    Andrew Dauber, MD, Chief of Endocrinology at Children's National Medical Center, Washington, D.C.
    Fernando Cassorla, MD, Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research, University of Chile
    Virtual KOL Event: Review of Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency Wednesday, December 6, 2023 | 1:30 PM EST
    To register for the virtual KOL Event, please click through the link here .

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Retrieved on: 
Monday, November 20, 2023
MTD, Neurology, Neoplasm, PSTV, Index, IND, University of Texas System, Catheter, SNO, EBRT, Neuro-oncology, Plus, Neuro, Decompression (diving), MD, Doctor of Philosophy, Therapy, Clinical trial, Standard of care, CED, Society, Annual general meeting, Bevacizumab, MFD, Plus Therapeutics, NIH, Patient, University, Safety, Phase II, SOC, Radiation, KOL, Pharmaceutical industry

The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.

Key Points: 
  • The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.
  • Rhenium (186Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.
  • Plus Therapeutics is hosting a virtual KOL event today, November 20, 2023 at 10:00 am ET to discuss the data presented at SNO.
  • A replay of the event will be available on Investor Relations section of the Plus Therapeutics website after the event.